EyePoint's DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says

MT Newswires Live10-20 23:14

EyePoint Pharmaceuticals' (EYPT) readout from its Diabetic Macular Edema trial is a key catalyst after missing the endpoint in its wet age-related macular degeneration, or wAMD, study, RBC Capital Markets analysts said in a Tuesday note.

EyePoint shares tanked on Monday after the company's late-stage trials of Duravyu in wAMD failed to meet the primary endpoint.

RBC said that with Duravyu missing the endpoint in wAMD trials, along with a prior miss in non-proliferative diabetic retinopathy, there is less confidence in the drug's success in another indication without additional data.

Analysts said EyePoint's shares will trade rangebound until the readout from its Diabetic Macular Edema, expected in Q4 2027.

RBC retained a sector perform, speculative risk, rating on the stock, but lowered its price target to $1 from $5.

Shares of the company were up 3.6% in Tuesday trading.

Price: 0.46, Change: +0.02, Percent Change: +4.09

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment